Good afternoon. Thank you for joining us today for the TOMI Environmental Solutions Investor Update Conference Call. On today’s call is TOMI’s Chief Executive Officer and Chairman of the Board, Dr. Halden Shane; TOMI’s Chief Operating Officer, E.J. Shane; and TOMI’s Chief Financial Officer, Nick Jennings. Dr. Shane will provide an overview of recent business highlights, financials, and future plans, E.J. and Nick will be available for the Q&A. A telephone replay of today’s call will be available through April 15, 2024, the details of which are included in the company’s press release dated April 1, 2024. A webcast replay will also be available at TOMI’s website, www.tomimist.com. Please note that information contained within this presentation is relevant only to the date of which it was recorded, April 1, 2024. And you are therefore advised that time-sensitive information may no longer be accurate at the time of any replay. Certain written and oral statements made by management of TOMI may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements should be evaluated in light of important risk factors that could cause actual results to differ materially from our anticipated results. The information provided in this conference call is based upon the facts and circumstances known at this time. The company undertakes no obligation to update these forward-looking statements after the date of this call. In addition, TOMI will discuss certain non-GAAP financial measures during this call. The company uses its non-GAAP measures because it believes they provide useful information about operating performance that should be considered by investors in conjunction with the GAAP measures. A reconciliation of these non-GAAP measures to comparable GAAP measures is included in the earnings release dated April 1, 2023. I will now turn the call over to TOMI’s Chairman and Chief Executive Officer, Dr. Halden Shane. Please go ahead.

Good afternoon, everyone, and thank you for joining the TOMI Environmental earnings call. I hope everyone had a nice Easter Sunday. Today, we will provide operating and financial results for the full-year 2023 along with an update on a few key current focuses for the company. During our 2023 calendar year, we delivered multiple custom-engineered systems to key customers, diversified our product lines to support our expanding customer base, and the related utilization of our SteraMist technology, and continue to build out our sales infrastructure through the expansion of our distribution network. Our year-over-year revenue declined due to the timing of certain customer orders and the frustrating long approval processes. There was tremendous progress made in 2023 within the company, and we continue to do business with premier companies around the world. Our list of clients keeps getting larger, and our latest product mix with the SteraMist Transport, SteraMist Integrated System, NV Plus, and Hybrid puts us in a great position to provide much improved financial results moving forward. As stated throughout last year, we remain focused on expanding our internal and external sales infrastructure and business development initiatives. Last year, we expanded our presence both domestically and internationally with new customers across our division, independent sales representatives, and broader distribution network to the United States. Most recently in November of 2023, we announced the addition of Sterile Grow, a United States-based distributor and consultation company in the food and cannabis market. Sterile Grow has demonstrated noteworthy achievements in the cannabis and food markets, specializing in controlled environment agriculture, particularly in integrating systems for large scale indoor cannabis cultivation. In November 2023, we entered into a consultant agreement with BEAMS, LLC to strengthen and expand the TOMI SteraMist network, and increase business development in the commercial market. BEAMS, LLC brings over 20 years of experience establishing strategic vision and direction for large institutions and companies spanning multiple industries, including higher education, not-for-profit, healthcare, consultancy, hospitality, and pharmaceutical sectors. Our sales infrastructure is in a much better place now compared to where we were at last year at this time, and we anticipate the increased bandwidth of our internal and external sales channels will have a positive impact on our revenue in 2024 and beyond. Demand for our CES has grown as we completed and delivered four CES systems in 2023, expanding our growing portfolio of projects. In the first quarter, we delivered a CES system to Orna Therapeutics, a leading biotechnology company located in Massachusetts. During the second quarter, we delivered an 11 applicator CES system to Avid Bioservices for implementation in Avid's new purpose-built viral vector development and manufacturing facility in Costa Mesa, California. During the third quarter of 2023, we delivered a three applicator CES system to the Ragon Institute of MGH, MIT, and Harvard for implementation in their research and clinical lab located in Cambridge, Massachusetts. In the third quarter of 2023, we delivered our CES hybrid system to Indigo Pharmaceuticals in Las Vegas, Nevada. We anticipate these additional systems will not only contribute to growth in our solution revenues moving forward, but will also lead to more referrals as they serve as a great marketing tool for us. Our brand recognition continues to grow market share as we march forward towards becoming the standard in the industry. We continue to diversify our base of products in 2023 with the introduction of SteraMist Hybrid and SteraMist Transport to support our ongoing commitment to providing superior disinfection and decontamination solutions for our growing customer base. The company remains active in our marketing initiatives and attended and presented our SteraMist brand of products at seven different trade shows during the fourth quarter alone. Our in-house service team is performing well. The SteraMist iHP service team saw a year-over-year growth of 13% through December and is continuing to perform well through the first quarter of this year. Earlier this month, we announced a groundbreaking study demonstrating the effectiveness of our solution against Foot-and-Mouth Disease Virus, FMDV. This significant advancement supports the company's submission for an additional EPA label. During 2023, we also completed a study conducted in accordance with the U.S. Department of Defense Biological Select Agents and Toxins Biorisk Program Office, which demonstrated SteraMist iHP as an effective technology for decontamination of biological toxoid and a study funded by the USDA and NIFA which demonstrated SteraMist iHP as an effective treatment of Deformed Wing Virus, known as DWV, contaminated hive substrates. The following are our company's forthcoming initiatives with both new and existing partners, insights into our product development endeavors and our strategies in place to drive revenue growth. Our revenue numbers for 2023 are not an accurate reflection of the progress we made during the year positioning the business for long-term growth. The strength of our pipeline comprised of key players in various industries gives us confidence. Key objectives include closing more CES or custom-engineered system sales, driving future revenue growth, ensuring that current CES installations are fully qualified and begin generating the anticipated BIT solution revenue, driving traction for the SIS or SteraMist Integrated System, thus fostering repeat business with OEMs of decontamination and closures, all while maintaining growth of the iHP corporate service revenues and expanding capital equipment purchases of our mobile equipment to both existing and new customers and distributors. To increase the success rate of winning bids for the CES custom engineered system, we are focusing on several key areas. Customers now have many options available to them in the implementation of SteraMist iHP as their decontamination solution. With CES emerging as a preferred choice for many, a crucial factor in securing successful CES bids lies in perfect timing and budget. This involves aligning the design, construction and budget aspects of a project built to create an optimal environment for SteraMist CES or any fully permanent automated system to be their choice. With these elements aligning our chances of winning these large bids increased significantly. One advantage, TOMI Environmental is currently enjoying is the cultivation of strategic contacts at these important moments. For instance, a recent successful bid wasn't initially solicited for our technology. It was at a primary interest for the end user. However, the designers of the project recommended and preferred our solution leading to a SteraMist win. We are actively entering into more and more relationships with these designers and construction firms to expand our outreach. By staying connected and informed about upcoming projects, we can position ourselves for success. Our internal initiatives aimed at enhancing communication and engagement are well underway, and we are confident that these efforts will yield positive results. Currently, we are in discussions with many companies regarding approximately 60-plus bids involving some sort of TOMI SteraMist integration over the many coming years, extending beyond the immediate fiscal period. Our second initiative involves ensuring that all 15 installations are operational and generating BIT solution revenue. To date, the final qualifying steps for six of our 15 installations are coming to a close, with the last expected to be completed by June of this year. We anticipate that once fully functional and operational, BIT solution revenue streams will equate to approximately $600,000 for our current bids only, assuming each facility maintains their current planned production schedules. While the SIS plan translates into less BIT solution revenue than the CES product due to the smaller scale of enclosures, its significance lies in enhancing TOMI's reputation as a versatile and user-friendly decontamination solution technology. The ability to offer quick and effective solutions for biological safety cabinets, BSCs, decontamination chambers, and various other enclosures for medical devices reinforces our position as a leading decontamination solution provider. We are currently engaged in communication and testing and registration procedures to ensure the efficacy and compliance of these solutions, further solidifying our presence in the market. iHP service revenue has been a steady and reliable source of income for our company, consistently showing growth over time. It serves as our entry point into many organizations, allowing us to showcase the effectiveness of our solution firsthand. Once clients experience the quality of our services, they often choose to engage with us for additional purchases. However, in today's economic climate, budget considerations often influence decision-making. As a result, many clients opt for routine service treatments that align with their financial plans. This trend reflects the current market dynamics and budget constraints faced by businesses. In addition to these new launches, we anticipate a surge in sales for our legacy surface unit and the well-received SteraPak handheld devices. This growth will be facilitated by collaborative efforts with Patty Olinger of BEAMS in revamping our TOMI service network. The SteraMist Pro certified program represents a significant evolution from the TOMI service network. It will not only extend its reach internationally, but also broaden its scope beyond remediation companies to include in-house service providers. The program will offer top-tier training branches covering various aspects from SteraMist usage to infectious disease management and indoor air quality control. Participation in the program will entail an annual fee, granting access to continuous learning opportunities, regional conferences, and future affiliate products. Additionally, members can expect roundtable discussions and other collaborative platforms to facilitate knowledge sharing and networking. This initiative reaffirms our commitment to providing comprehensive support and resources to our partners worldwide. I want to highlight the ongoing momentum of our partnership initiatives, encompassing collaborations with key entities such as Francis Coppi, ambulance manufacturers, both directly and through our Canadian distributor, Vizient GPO, Nestle, and other committed European distributors, Universal Disinfection. These partnerships remain pivotal to our growth strategy, providing us with access to new markets and opportunities. We will shortly announce recent developments, including advancements in fentanyl testing capabilities, the pursuit of our new EPA label, whether or not SteraMist can play a role in controlling the environmental impact of PFOSs and PFOAs, also known as the forever chemicals, along with follow-up on our marketing plan and how to take advantage of the loss in the medical sterilization industry as approximately 20 billion medical devices are sterilized per year with ethylene oxide. The EPA regulation is restricting its usage, which could create a significant market void that may be filled with alternative sterilization processes, such as TOMI's patented binary ionization technology. A brief overview of our financial results for the full 2023 compared to the full-year 2022. Our consolidated net revenue was $7,355,000 compared to $8,338,000. The timing of orders, including holidays, the masses of signatures needed for order progression affected our revenue. Consolidated gross profit was 58.3% compared to 60.7%. The decrease in gross profit was due to our product mix, more CES than mobile. The consolidated operating loss was $3,349,000 compared to $2,822,000. Our consolidated net loss was $3,403,000, or $0.17 per basic and diluted share, compared to $2,880,000, or $0.15 per basic share. Moving to the balance sheet as of December 31st, our cash-to-cash equivalent was approximately $2.3 million, working capital was $7.9 million, and our shareholder equity was $8.4 million. As far as positive feedback from investors, I was just notified that Highwire, the contractor success platform for builders and owners of capital projects, has just announced the recipient of its prestigious safety award. TOMI Environmental Solutions received the Gold Safety Award, stating, "Management systems are critical to any company's ability to deliver successful outcomes and, most importantly, to keep their employees safe." TOMI Environmental Solutions has done a remarkable job implementing a strong safety management system resulting in exceptional safety performance and results. With that being said, I want to thank you all for joining us today and for your unwavering support as investors and followers of our company. A big thank you to our team around the world who has helped lead the foundation for our company to become the world's leader in the disinfection and decontamination space. We are correctly situated with the right conversations taking place to move us forward, replace the archaic methods, and increase the idea of proactive over reactive approaches. We'll now open to questions and answers.

Certainly. At this time, we will be conducting a question-and-answer session. Thank you. Your first question is from Jack Williams from Warren Capital. Your line is live.

Hi, thanks for taking the question. So, you guys launched a handful of new products in 2023. Can you provide some color on if these new products expand your addressable market, if they're mostly kind of for existing customers or verticals?

Okay. E.J., you want to take that if you can?

Yes, certainly. Hello, everyone. So, the new product launches are for both current customers and new customers. They're made and designed for a variety of different industries. For example, the transport is primarily designed for emergency services. The NV Plus and the SteraMist Integrated System standalone version are two that will be launched live at Interfax in 15 days, in New York. And we look forward to seeing a lot of results there, considering they were designed with a lot of the customers we will be meeting there as well.

Got it, it's helpful. Thank you.

Thank you. Your next question is coming from John Nelson. Your line is live.

Hi, Halden and team. Thank you for taking my questions. My first question is, do you have the cash resources to get you to profitability?

We believe we do at the moment, and we do have the resources in place, yes.

Okay, good. And can you give us some updates on some of the various opportunities that you've been exploring in past sessions regarding food produce, hospital cleaning, and semiconductor plants, and service pro-type operations?

Sure. So, I mean, yes, as mentioned on the call, we're revamping the TSN into a professional certified program that we will be issuing various badges as levels of achievement. And we think that bringing that domestically and internationally with the new hires we have will be extremely beneficial to the company. As far as the ambulances, we have customers or distributors that have customers in both North America, Canada, and the United States that are interested in our transport, and we're hoping to see movement this year in that area. Food safety is, every time I give a quarterly update, seems to be getting busier and busier. There's tremendous interest out there in the food safety end, from both transportation, processing, and general protective food safety as a country and as a world, because obviously food prices are going up and food is becoming more scarce. So, that I think will be fighting for the lead among our divisions with life sciences in the very near future. Hospitals, we are still coming out with new marketing this year for the hospital markets, and with some of the advancements in some of our new pathogens, I think that they're going to be looking to replace a lot of the excessive disinfection equipment that they bought during the COVID pandemic, which by now is either not working or they're ready for something new. So, we see a pretty bright horizon in all those areas. I don't know if I missed any, but I know semiconductors you mentioned, but we really haven't done much with that yet, but I think it's going to be definitely another market that should be interested in our product.

Okay. And what about exploring the use of SteraMist in addressing the substitution for ethylene oxide?

Right, I mentioned that on the call too. I think that that's going to be a very interesting new niche for us. Now, the point being this ethylene oxide, the EPA is putting some real restrictions on both from an indoor environmental and outdoor environmental aspect. And it has a lot to do with exhausting out from these large medical sterilization facilities, medical material supplies equipment, and it's going to be an expensive process to change their exhaust system. So, I think some of them will end up probably changing it and stay with ethylene oxide. Many will be looking for alternatives that are more eco-friendly and less cost-generic. So, I think we have a great opportunity here. We still have a little bit of regulatory stuff to go through that we're working on and there should be some interesting updates in future earnings calls about that.

Okay. And I know you're exploring the possibilities of using your solution in addressing the PFAS and PFOA problems. Can you give us any more details about how you would go about using your product to treat that problem?

Well, so I mean, I really can't. I can do it on a personal basis, which I will right now, but as a company, with the amount of employees we have and with the amount of effort and work as you just heard that we're doing, it's not up there. It's on our list to accomplish this year. I think both from water safety and from these areas where these yards are that they keep throwing this, all these forever chemicals. I think we potentially have a shot at breaking them down and eliminating it, whether they're put into certain bins that we treat or the process itself. So, we're still looking at it. I'm more than anyone in the company and I'm hoping that because that would be, if we're able to break into any aspect of that, whether it's the way that these products, these forever chemicals are breaking into our food supply through the soil and through the roots of plants or whether it's into the water supply or literally that they're just toxic in the environment, will be a great win both from a financial aspect of our company and from a humanitarian aspect of what this product can do for the world.

Good. Thank you. And then, you mentioned the delays in the fourth quarter revenues. Would you expect most of that to catch up in Q1 or just over the next three or four quarters?

I think it's going to be a bit unusual. The second and third quarters, which are typically not our strongest, are expected to be quite robust for us. I believe we will start showing profitability by that time. Once we achieve that, we can look ahead positively into 2025 and 2026. We have a significant number of bids and interest from potential clients. Just before this call, I noticed inquiries from three different sectors interested in our product over the competition. We have a solid team and a strong strategy, and as mentioned on the call, the right initiatives to ensure we become a profitable company.

Okay, good. Addressing the competition, I see TOMI having a far superior product in the markets you are targeting. Has there been any change in the competitive landscape in the last three to six months?

I mean, I don't follow it as much as I used to, because when it comes down to it, nothing can compete with us from a timing and efficacy standpoint. So, the fact that we're not caustic, that we're the quickest and probably the most effective, it's going to be hard to find anybody competing unless they are violating our patent and then we'll go after them. But at the moment, we need to grow the company and we need to close out these deals going forward and to maintain and become profitable and maintain profitability.

Okay, excellent. Thank you very much.

Thank you very much for your support. And I know it's been a while.

Thank you. That concludes our Q&A session. I'll now hand the conference back to management for closing remarks. Please go ahead.

Once again, I just want to thank everybody for your support and for joining us today. And I hope you have a great rest of the year.